Celebrex Name Keeps Drug Off Minnesota Health-System Formulary
Executive Summary
The potential for Searle/Pfizer's arthritis therapy Celebrex to be confused with other products is keeping the drug off the formulary of Minneapolis-based Fairview Health Services, a hospital pharmacy director told a National Coalition on Health Care medical errors conference Feb. 22 in Washington, D.C.
You may also be interested in...
Celebrex Educational Campaign Or Name Change Expected By End Of May
A decision on instituting a name change or educational campaign for Searle/Pfizer's Celebrex is expected by the end of May.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials